That poster's Rett calculations valued treatment at USD$32,000 and they are only factoring 20% penetration. They came to a Europe/ Asia valuation id USD$115 per share.
Then they added 4 x drugs with success in NNZ2591 and came out USD$320 per share all up.
Now.....with Retts treatement actually coming in at USD$350,000 per annum FOR REAL and upping penetration to ...say.....30/40 % and I want this person's calcualtions to be bang on because we are going to ....USD$3000 per share.
Thats like.........bitcoin silly.
MWAHAHHAHHAHHAHHAHHAHAHHHAHAHAHHAAHHA
Let’s compare valuations based off Acadias price for Daybue, page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |